TwinStrand wins patent lawsuit as GSK’s hepatitis B therapy receives Japanese approval
TwinStrand Biosciences, a DNA sequencing spin‑out from the University of Washington, announced it has prevailed in a patent infringement lawsuit against a California‑based competitor.
The court’s decision upholds TwinStrand’s patents related to its sequencing technology, securing its intellectual‑property position in the market.
In separate news, GlaxoSmithKline reported that its hepatitis B drug has been approved for use in Japan, expanding the product’s availability in the Asian market.
The approval adds to GSK’s portfolio of hepatitis treatments and may boost its presence in the region.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that